Medpace, a privately held, global, full-service contract research organization (CRO) announced that it has acquired MediTech Strategic Consultants B.V. (MediTech), a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices.

MediTech joins Medpace as a strategic European acquisition, expanding Medpace’s European device capabilities both in the development of trial designs and regulatory strategies towards CE Mark, in addition to the conduct of clinical trials and authorized representative and quality system support towards ISO 13485. This acquisition, combined with Medpace’s existing medical device division, provides a unique global solution for medical device development, allowing seamless support through all stages of the medical device lifecycle.

MediTech was founded in 2000 by Carla Kikken-Jussen, President & CEO, an industry expert with over 25 years of experience in the medical device industry covering medical device clinical research and European regulatory affairs. MediTech has supported clinical trials on wide variety of medical devices including therapeutic areas such as ophthalmology, cardiovascular, gastroenterology, orthopedics, and pulmonology medical devices. Ms. Kikken-Jussen will continue to lead MediTech with her team members, bringing extensive experience to Medpace.

"I am pleased to welcome Carla Kikken-Jussen and the MediTech team to Medpace,‖ said Dr. August Troendle, President and CEO, Medpace. ―MediTech’s expertise complements and broadens our global medical device service offering. MediTech is well respected in both Europe and the US and this strategic acquisition fully supports Medpace’s growth and provides our sponsors a wide range of regulatory and clinical expertise across North America and Europe along with expanded operational capacity."